L-Arginine, Symmetrical and Asymmetrical Dimethylarginine (SDMA/ADMA) in Acute Kidney Injury (AKI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the association between acute kidney injury and serum levels symmetrical and asymmetrical dimethylarginine (SDMA/ADMA) and their assumptive influence on mortality, renal function and on arterial stiffness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ADMA Levels in End-Stage Renal Disease

NCT00350974

Chronic Kidney Disease Hypertension

COMPLETED

The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

NCT01317186

Metabolic Diseases Chronic Kidney Disease

UNKNOWN

Dcr3 Levels in Blood and Urine on Renal and Patient Prognosis in Patients With Acute Kidney Injury

NCT05735093

Acute Kidney Injury

UNKNOWN

Risk Factors and Machine Learning Model for Diuretics Related Acute Kidney Injury

NCT05527054

Diuretic Toxicity Acute Kidney Injury

ACTIVE_NOT_RECRUITING

Acute Kidney Injury and Acute Kidney Disease in COVID-19

NCT04353583

Acute Kidney Injury Corona Virus Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute kidney injury (AKI) is a frequent complication with severe implications deteriorating overall prognosis. Nitric oxide (NO)-signal transduction plays an important role in mediating renal damage. NO is produced by NO-synthase (NOS) with L-arginine as its substrate. Endogenous L-Arginine derivatives, asymmetric and symmetric dimethylarginines (ADMA/SDMA), inhibit NO-production directly (AMDA) by blocking NOS activity or indirectly (SDMA) by blocking cellular L-Arginine uptake.

It is well known that SDMA and ADMA are markers of renal function (SDMA) and cardiovascular risk (ADMA/SDMA) in patients with chronic kidney disease (CKD). Moreover, ADMA and SDMA possibly even trigger cardiovascular risk in patients with CKD. However, there is only little information about the regulation and the influence of ADMA/SDMA in acute kidney injury.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

acute kidney injury

Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
* no started renal replacement therapy (e.g. dialysis)

Exclusion Criteria

* dialysis or continuous venovenous hemofiltration before recruitment
* no recovery from kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
* palliative care
* life expectancy is severely limited (\< six months) due to preexisting malignancy or other disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes